Literature DB >> 18632606

CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.

Phuongmai Nguyen1, Hengmi Cui, Kheem S Bisht, Lunching Sun, Krish Patel, Richard S Lee, Hiroyuki Kugoh, Mitsuo Oshimura, Andrew P Feinberg, David Gius.   

Abstract

The CTCF paralog BORIS (brother of the regulator of imprinted sites) is an insulator DNA-binding protein thought to play a role in chromatin organization and gene expression. Under normal physiologic conditions, BORIS is predominantly expressed during embryonic male germ cell development; however, it is also expressed in tumors and tumor cell lines and, as such, has been classified as a cancer-germline or cancer-testis gene. It has been suggested that BORIS may be a pro-proliferative factor, whereas CTCF favors antiproliferation. BORIS and CTCF share similar zinc finger DNA-binding domains and seem to bind to identical target sequences. Thus, one critical question is the mechanism governing the DNA-binding specificity of these two proteins when both are present in tumor cells. Chromatin immunoprecipitation (ChIP) in HCT116 cells and their hypermethylated variant showed that BORIS binds to methylated DNA sequences, whereas CTCF binds to unmethylated DNA. Electromobility shift assays, using both whole-cell extracts and in vitro translated CTCF and BORIS protein, and methylation-specific ChIP PCR showed that BORIS is a methylation-independent DNA-binding protein. Finally, experiments in murine hybrid cells containing either the maternal or paternal human chromosome 11 showed that BORIS preferentially binds to the methylated paternal H19 differentially methylated region, suggesting a mechanism in which the affinity of CTCF for the unmethylated maternal allele directs the DNA binding of BORIS toward the paternal allele.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632606      PMCID: PMC2731476          DOI: 10.1158/0008-5472.CAN-08-1005

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer.

Authors:  D Takai; F A Gonzales; Y C Tsai; M J Thayer; P A Jones
Journal:  Hum Mol Genet       Date:  2001-11-01       Impact factor: 6.150

2.  Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene.

Authors:  A C Bell; G Felsenfeld
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

3.  CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus.

Authors:  A T Hark; C J Schoenherr; D J Katz; R S Ingram; J M Levorse; S M Tilghman
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

4.  Transcriptional activation and repression by Fos are independent functions: the C terminus represses immediate-early gene expression via CArG elements.

Authors:  D Gius; X M Cao; F J Rauscher; D R Cohen; T Curran; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

5.  Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2.

Authors:  Hengmi Cui; Patrick Onyango; Sheri Brandenburg; Yiqian Wu; Chih-Lin Hsieh; Andrew P Feinberg
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

6.  Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive.

Authors:  C Kanduri; V Pant; D Loukinov; E Pugacheva; C F Qi; A Wolffe; R Ohlsson; V V Lobanenkov
Journal:  Curr Biol       Date:  2000-07-13       Impact factor: 10.834

7.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.

Authors:  Ina Rhee; Kurtis E Bachman; Ben Ho Park; Kam-Wing Jair; Ray-Whay Chiu Yen; Kornel E Schuebel; Hengmi Cui; Andrew P Feinberg; Christoph Lengauer; Kenneth W Kinzler; Stephen B Baylin; Bert Vogelstein
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

8.  Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast.

Authors:  Andrew R Green; Sophie Krivinskas; Peter Young; Emad A Rakha; E Claire Paish; Desmond G Powe; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2008-01-23       Impact factor: 4.872

9.  The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation.

Authors:  Petar Jelinic; Jean-Christophe Stehle; Phillip Shaw
Journal:  PLoS Biol       Date:  2006-10       Impact factor: 8.029

Review 10.  The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.

Authors:  Elena M Klenova; Herbert C Morse; Rolf Ohlsson; Victor V Lobanenkov
Journal:  Semin Cancer Biol       Date:  2002-10       Impact factor: 15.707

View more
  21 in total

1.  TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing.

Authors:  Ryan J Marina; David Sturgill; Marc A Bailly; Morgan Thenoz; Garima Varma; Maria F Prigge; Kyster K Nanan; Sanjeev Shukla; Nazmul Haque; Shalini Oberdoerffer
Journal:  EMBO J       Date:  2015-12-28       Impact factor: 11.598

Review 2.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 3.  Chromatin insulators: a role in nuclear organization and gene expression.

Authors:  Jingping Yang; Victor G Corces
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

4.  Intronic promoter drives the BORIS-regulated expression of FerT in colon carcinoma cells.

Authors:  Adar Makovski; Etai Yaffe; Sally Shpungin; Uri Nir
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

5.  Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.

Authors:  Koji Okabayashi; Tomonobu Fujita; Junichiro Miyazaki; Tsutomu Okada; Takashi Iwata; Nobumaru Hirao; Shinobu Noji; Nobuo Tsukamoto; Naoki Goshima; Hirotoshi Hasegawa; Hiroya Takeuchi; Masakazu Ueda; Yuko Kitagawa; Yutaka Kawakami
Journal:  Cancer Sci       Date:  2012-07-16       Impact factor: 6.716

6.  Exploitation of the interaction of measles virus fusogenic envelope proteins with the surface receptor CD46 on human cells for microcell-mediated chromosome transfer.

Authors:  Motonobu Katoh; Yasuhiro Kazuki; Kanako Kazuki; Naoyo Kajitani; Masato Takiguchi; Yuji Nakayama; Takafumi Nakamura; Mitsuo Oshimura
Journal:  BMC Biotechnol       Date:  2010-05-06       Impact factor: 2.563

7.  The structural complexity of the human BORIS gene in gametogenesis and cancer.

Authors:  Elena M Pugacheva; Teruhiko Suzuki; Svetlana D Pack; Natsuki Kosaka-Suzuki; Jeongheon Yoon; Alexander A Vostrov; Eugene Barsov; Alexander V Strunnikov; Herbert C Morse; Dmitri Loukinov; Victor Lobanenkov
Journal:  PLoS One       Date:  2010-11-08       Impact factor: 3.240

8.  BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression.

Authors:  Phuongmai Nguyen; Gil Bar-Sela; Lunching Sun; Kheem S Bisht; Hengmi Cui; Elise Kohn; Andrew P Feinberg; David Gius
Journal:  Mol Cell Biol       Date:  2008-09-02       Impact factor: 4.272

9.  Endonuclease-sensitive regions of human spermatozoal chromatin are highly enriched in promoter and CTCF binding sequences.

Authors:  Ali Arpanahi; Martin Brinkworth; David Iles; Stephen A Krawetz; Agnieszka Paradowska; Adrian E Platts; Myriam Saida; Klaus Steger; Philip Tedder; David Miller
Journal:  Genome Res       Date:  2009-07-07       Impact factor: 9.043

10.  Dose-dependent activation of putative oncogene SBSN by BORIS.

Authors:  Daria Gaykalova; Rajita Vatapalli; Chad A Glazer; Sheetal Bhan; Chunbo Shao; David Sidransky; Patrick K Ha; Joseph A Califano
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.